ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2627

Development and Validation of a Novel Score System to Guide Diagnostic Procedures in Children with Concerns of Chronic Nonbacterial Osteomyelitis

Rajdeep Pooni1, Sarah Menashe2, Melissa Oliver3, Anja Schnabel4, Eveline Wu5, Zhaoyi Wang6, Claire Yang7, Achille Marino8, Cassyanne Aguiar9, Johnathan Akikusa10, Ummusen Kaya Akca11, Beverly Almeida12, Simone Appenzeller13, Ozge Basaran14, Matthew Basiaga15, David Cabral16, Martina Capponi17, nathan Donaldson18, Bugra Egeli19, Emily Fox20, Antonella insalaco21, Ramesh Iyer22, Annette Jansson23, Inna Kostik24, Mikhail Kostik25, Leonard Kovalick26, Katia Kozu27, Sivia Lapidus28, Tzielan Lee29, Aleksander Lenert30, Kamran Mahmood31, Edoardo Marrani32, Doaa Mosa33, Alexander Mushkin34, Farzana Nuruzzaman35, Karen Onel36, Manuela Pardeo21, Trang Pham22, Lauren Potts37, Athimalaipet Ramanan38, Angelo Ravelli39, Nathan Rogers18, Ian Muse40, Micol Romano41, natalie Roseenwasser22, T. Shawn Sato42, Gabriele Simonini43, jennifer Soep18, Sara Stern44, Alexander Theos45, Lori Tucker46, Leslie Vogel2, Shima Yasin30, Katerina Bouchalova47, Alison Hendry48, Kevin Cain49, Hermann Girschick50, Fatma Dedeoglu19, Christian Hedrich51, Ronald Laxer52, Polly Ferguson30, Seza Ozen53 and Yongdong Zhao54, 1Stanford University, Berkeley, CA, 2Seattle Children's Hospital, University of Washington School of Medicine, Seattle, WA, 3Riley Hospital for Children, Indiana University School of Medicine, Indianopolis, IN, 4Pediatric Rheumatology, Department of Pediatrics, University Hospital Carl Gustav Carus, Dresden, Germany, 5University of North Carolina School of Medicine, Chapel Hill, NC, 6University of Washington School of Medicine, Seattle, Seattle, WA, 7Seattle Children's Hospital, Seattle, 8ASST Gaetano Pini-CTO, Milan, Italy, Milan, Italy, 9Children's Hospital of The King's Daughters, Eastern Virginia Medical School, Norfolk, VA, 10Royal Children's Hospital, Melbourne, Australia, 11Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, 12Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 13Unicamp, Campinas, SP, Brazil, 14Hacettepe University, Ankara, Turkey, 15Mayo Clinic, Rochester, MN, 16BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 17Sapienza University, Rome, Italy, 18University of Colorado School of Medicine, Aurora, CO, 19Boston Children's Hospital, Boston, MA, 20Children's Mercy Hospital, Kansas City, MO, 21IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 22University of Washington School of Medicine, Seattle, WA, 23Dr. von Hauner Children´s Hospital, Munich, Germany, 24Sanatorium for children Detskie Dyuny, Saint-Petersburg, Russia, 25Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, 26The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 28Hackensack University Medical Center, Montclair, NJ, 29Stanford University School of Medicine, Palo Alto, CA, 30Carver College of Medicine, University of Iowa Hospitals & Clinics, Iowa City, IA, 31Alder Hey Children's Hospital, Liverpool, United Kingdom, 32ERN ReCONNET center, Meyer Children's Hospital-IRCCS, Firenze, Italy, 33Mansoura University Hospital, Mansoura City, Egypt, 34Science-Research Institute of Phthisiopulmonology, Saint-Petersburg, Russia, 35Renaissance School of Medicine at Stony Brook University, Stony Brook, NY, 36HSS, New York, NY, 37Patient Research Partner, Long Beach, CA, 38Bristol Royal Hosp for Children, Bristol, United Kingdom, 39IRCCS Giannina Gaslini, Genoa, Italy, 40Seattle Children's Research institute, Seattle, WA, 41Behcet and Autoinflammatory Disease Center, Western University, London, ON, Canada, 42University of Iowa, Iowa City, 43Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, 44University of Utah, Salt Lake City, UT, 45Patient/parent partner, Washington DC, DC, 46BC Children's Hospital, Vancouver, BC, Canada, 47Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Olomouc, Czech Republic,48Division of Medicine Middlemore Hospital Counties Manukau District Health, Auckland, New Zealand, 49University of Washington, Seattle, WA, 50Vivantes Clinic Friedrichshain, Berlin, Germany, 51University of Liverpool, Liverpool, United Kingdom, 52SickKids, Toronto, ON, Canada, 53Department of Pediatrics, Hacettepe University, Ankara, Turkey, 54Seattle Children's Research institute, Seattle, WA

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Abstracts: Pediatric Rheumatology – Clinical II

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disease. The diagnosis of CNO is made by recognizing typical clinical and imaging presentation and excluding mimicking diseases. In patients with clinical characteristics concerning for mimicking diseases or those with atypical presentation of CNO, a bone biopsy may be necessary to aid the clinical diagnosis. We aimed to develop and validate a novel score system to identify subsets of patients with very low or very high probability of CNO, prior to the decision of whether to do a bone biopsy.

Methods: A total of 960 cases collected from 31 hospital centers across 6 continents were used. Cohort was comprised of 672 pediatric CNO cases and 288 CNO mimicker cases.  Demographic, clinical, laboratory, and imaging findings were collected. At least 12 months follow up was required for CNO cases and for mimicker cases unless confirmatory diagnostic and laboratory findings of a mimic condition were uncovered.  Cases were randomly assigned into development and validation cohorts and the development cohort was used for model creation.  Imaging findings plus routinely measured features were used in logistic regression with stepwise deletion.  Regression coefficients from this model were rounded to integer weights to compute a score, with higher scores indicating a greater likelihood of CNO.  This model was used to sort patients into ordered categories based on likelihood of CNO, then applied to the Validation Cohort to obtain an unbiased estimate of model performance.

Results: About 80% of mimicker cases in the total sample were from infectious or malignant causes which often require bone biopsies (Table 1).  Imaging features and routinely collected features considered for inclusion in the initial model are shown in Table 2.  Clinical characteristics considered for the initial model are shown in Table 1 along with the corresponding weights for the final model.  Table 3 shows results of the final model applied to the Validation and Development Cohorts, with scores collapsed into 4 categories.  If a threshold of ≥ 1 is used, sensitivity is 75% and specificity is 88%. We propose: 1) for cases score ≤ -2, CNO is unlikely and hence focus should be on determining which mimic condition is present, with bone biopsy only if useful for that purpose ; 2) for cases score -1 or 0, bone biopsy is likely to be useful to determine whether infection or malignancy is present; 3) for cases score ≥ 1, CNO is highly likely and a bone biopsy may required if imaging or clinical features raise the suspicion of malignancy or infection.  Among the CNO cases scored ≥ 1 (n=252) in the Validation Cohort, 142 (56%) had a bone biopsy.  Under our proposal, many of these biopsies could be avoided. 

 

Conclusion: Our novel CNO score system derived from an international cohort showed it is possible to separate patients into categories based on minimally invasive tests.  This information can be useful in identifying cases for which a bone biopsy would be appropriate.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: R. Pooni: None; S. Menashe: None; M. Oliver: None; A. Schnabel: None; E. Wu: Pharming Healthcare, Inc, 1, 6, Sumitoma Pharma America, Inc, 1; Z. Wang: None; C. Yang: None; A. Marino: None; C. Aguiar: None; J. Akikusa: None; U. Akca: None; B. Almeida: None; S. Appenzeller: None; O. Basaran: None; M. Basiaga: CARRA, 5, Sjogren Foundation, 5; D. Cabral: None; M. Capponi: None; n. Donaldson: None; B. Egeli: None; E. Fox: None; A. insalaco: None; R. Iyer: None; A. Jansson: None; I. Kostik: None; M. Kostik: None; L. Kovalick: None; K. Kozu: None; S. Lapidus: None; T. Lee: None; A. Lenert: None; K. Mahmood: None; E. Marrani: None; D. Mosa: None; A. Mushkin: None; F. Nuruzzaman: None; K. Onel: None; M. Pardeo: None; T. Pham: None; L. Potts: None; A. Ramanan: Abbvie, 2, 6, Alexion, 2, Astra Zeneca, 2, Eli Lilly and Company, 2, 6, Novartis, 2, 5, 6, Pfizer, 6, Roche, 6, SOBI, 6, UCB, 2; A. Ravelli: AbbVie/Abbott, 2, 6, Alexion, 6, Galapagos, 2, Novartis, 2, 5, 6, Pfizer, 2, 6, SOBI, 6; N. Rogers: None; I. Muse: None; M. Romano: None; n. Roseenwasser: None; T. Sato: None; G. Simonini: None; j. Soep: None; S. Stern: None; A. Theos: None; L. Tucker: None; L. Vogel: None; S. Yasin: None; K. Bouchalova: None; A. Hendry: None; K. Cain: None; H. Girschick: None; F. Dedeoglu: UpToDate, 9; C. Hedrich: Merck, 5; R. Laxer: Akros pharma, 2, Eli Lilly canada, 2, Novartis, 2, Sanofi, 2, sobi, 2; P. Ferguson: None; S. Ozen: Novartis, 2, 6, SOBI, 2, 6; Y. Zhao: Bristol-Myers Squibb(BMS), 5.

To cite this abstract in AMA style:

Pooni R, Menashe S, Oliver M, Schnabel A, Wu E, Wang Z, Yang C, Marino A, Aguiar C, Akikusa J, Akca U, Almeida B, Appenzeller S, Basaran O, Basiaga M, Cabral D, Capponi M, Donaldson n, Egeli B, Fox E, insalaco A, Iyer R, Jansson A, Kostik I, Kostik M, Kovalick L, Kozu K, Lapidus S, Lee T, Lenert A, Mahmood K, Marrani E, Mosa D, Mushkin A, Nuruzzaman F, Onel K, Pardeo M, Pham T, Potts L, Ramanan A, Ravelli A, Rogers N, Muse I, Romano M, Roseenwasser n, Sato T, Simonini G, Soep j, Stern S, Theos A, Tucker L, Vogel L, Yasin S, Bouchalova K, Hendry A, Cain K, Girschick H, Dedeoglu F, Hedrich C, Laxer R, Ferguson P, Ozen S, Zhao Y. Development and Validation of a Novel Score System to Guide Diagnostic Procedures in Children with Concerns of Chronic Nonbacterial Osteomyelitis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/development-and-validation-of-a-novel-score-system-to-guide-diagnostic-procedures-in-children-with-concerns-of-chronic-nonbacterial-osteomyelitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-and-validation-of-a-novel-score-system-to-guide-diagnostic-procedures-in-children-with-concerns-of-chronic-nonbacterial-osteomyelitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology